Clinical

One step closer to saving a species!

In the last five years, two words have spread like wildfire, “Toad Medicine” (5-MeO-DMT) is in the mouths of celebrities, herpetologists, psychonauts, and curious people. This curiosity narrowed Incilius Alvarius to endangerment due to poaching and increased movement on the Sonoran roads. Fortunately, researchers at Mount Sinai Hospital and Columbia University greeted us with another synthetic alternative to stop harming the toads 4-F,5-MeO-PyrT.

Could this be a queue to stop seeing this toad as a “medicine” and see it as a living species once again and stop abusing it for personal benefit?

One step closer to saving a species! Read More »

Harm reduction 101: The harm reduction guide

This harm-reduction series will be sharing tips on how to have safe trips. Covering subjects such as psychedelic therapy, and psychedelic retreats, the importance of testing your compounds, set and setting, and the importance of having a plan and using a trip sitter.

In this chapter, we will be focusing on the importance of testing your substances and when to use each reagent, what is set and setting and their importance, the importance of tripsitters (buddy-system), and how to create a safety plan when using psychedelics.

Harm reduction 101: The harm reduction guide Read More »

Harm reduction 101: Psychedelic therapy and psychedelic retreats

This harm-reduction series will be sharing tips on how to have safe trips. Covering subjects such as psychedelic therapy, and psychedelic retreats, the importance of testing your compounds, set and setting, and the importance of having a plan and using a trip sitter.

In this chapter, we will be covering the misconception of psychedelics alone being able to heal mental illnesses, and the processes behind psychedelic therapy, including what is integration, types of integration, and how to be safe in international retreats.

Harm reduction 101: Psychedelic therapy and psychedelic retreats Read More »

Psilocybin In the brain

Since the introduction of the Psilocybe genus to the western community, various genetic engineering experiences were made birthing various strains, among them the WillSolvem Peyote Strain.

Recent revolutionary research conducted by the Usona Institute unveiled for the first time the true crystal structure of psilocybin opening doors for new psilocybin analogs, such as CYB003, believed to hold the potential to treat major depressive disorder (MDD) and alcohol disorder. This analog is designed to have less variability in the plasma levels, a faster onset of action, shorter duration, and potentially be more tolerable versus oral psilocybin.

Along with the mycological and chemical discoveries, how the substance acts in the brain and its potential use for the treatment of clinical depression is also being explored together with the hypothesis of psilocybe altering the gut microbiome, thus creating a potential avenue for new pharmaceutical tools targeting the gut-brain axis.

Psilocybin In the brain Read More »

Shopping Cart